Venue: Ramada Frankfurt Messe
|Event Date/Time: Oct 27, 2010||End Date/Time: Oct 28, 2011|
|Registration Date: Oct 28, 2010|
|Early Registration Date: Jul 30, 2010|
New insights into the underlying mechanisms of previously untreatable disorders, has led to a flurry of activity and a host of new drugs in development.
However, the major bottleneck, and the biggest barrier to commercial exploitation, is clinical progression.
Drug development for CNS is still a risky business. With 100s of millions of Euros being spent on every clinical trial, it is now more important than ever to capitalise on research progress. The key to success is translating our ever growing knowledge of CNS disorders into well constructed, concise and most importantly conclusive clinical trials.
Inspired by the world's leading CNS drug developers (including Merck Serono, Johnson & Johnson, Novartis, AstraZeneca, Pfizer, F. Hoffman-La Roche, UCB, Merck & Co, Abbott and many other pioneering biotechs) youâ€™ll find an agenda that delivers practical value and provides you with a forum for frank and honest discussion.
What's on the agenda for Translational Neuroscience?
How to identify and validate CNS biomarkers
Methods for accelerating clinical development through neuroimaging strategies
How to capitalise on new platforms and the very latest innovative technologies in clinical development
Development of predictive pre-clinical assays in neurology. Where are the latest models going to come from?
Techniques to utilise biomarkers as endpoints for clinical progression
Why should you attend Translational Neuroscience?
To discover new strategies to identify biomarkers through proteomics and genomics
To understand how to validate clinical relevant biomarkers for use as endpoints
To learn about utilising functional imaging techniques in biomarker ID and clinical application
To understand the latest research efforts in the application of neuro-research into clinical trial design to streamline the drug approval success
To learn how to accelerate progress of drug candidates through the clinic and maximise the speed to market for your neuro-drug
To gain a multitude of new ideas and contacts to take back to your research organisation